Synergism at clinically attainable concentrations of aminoglycoside and β-lactam antibiotics

Thomas Hooton, A. D. Blair, M. Turck, G. W. Counts

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

We evaluated the in vitro synergistic activity at clinically attainable concentrations of combinations of aminoglycoside and β-lactam antibiotics against 30 gentamicin-resistant clinical isolates of gram-negative bacilli. All 56 pairs of 4 aminoglycosides and 14 β-lactams were evaluated. Combinations with amikacin demonstrated inhibitory synergistic activity in 29% of the assays, as compared with 22% for netilmicin (P = 0.018), 17% for gentamicin (P < 0.001), and 13% for tobramycin (P < 0.001). Among the β-lactams, combinations with cefoperazone, ceftriaxone, or cefpiramide (SM-1652) demonstrated inhibitory synergistic activity most often (39, 38, and 35% of the assays, respectively) and with ceforanide, cefsulodin, and imipenem least often (≤8% each). The most active combination was amikacin and ceftriaxone, with which 67% of the assays demonstrated inhibitory synergism. Isolates with high-level resistance to either antibiotic in a combination were unlikely to be inhibited synergistically by the combination. Further, combinations generally demonstrated little synergistic activity against isolates highly susceptible to β-lactams.

Original languageEnglish
Pages (from-to)535-538
Number of pages4
JournalAntimicrobial Agents and Chemotherapy
Volume26
Issue number4
StatePublished - Jan 1 1984
Externally publishedYes

Fingerprint

Lactams
Aminoglycosides
Anti-Bacterial Agents
Amikacin
Ceftriaxone
Gentamicins
Cefsulodin
Netilmicin
Cefoperazone
Tobramycin
Imipenem
Bacillus
cefpiramide

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

Synergism at clinically attainable concentrations of aminoglycoside and β-lactam antibiotics. / Hooton, Thomas; Blair, A. D.; Turck, M.; Counts, G. W.

In: Antimicrobial Agents and Chemotherapy, Vol. 26, No. 4, 01.01.1984, p. 535-538.

Research output: Contribution to journalArticle

@article{79c757df2628420aa7a2e18f36a98168,
title = "Synergism at clinically attainable concentrations of aminoglycoside and β-lactam antibiotics",
abstract = "We evaluated the in vitro synergistic activity at clinically attainable concentrations of combinations of aminoglycoside and β-lactam antibiotics against 30 gentamicin-resistant clinical isolates of gram-negative bacilli. All 56 pairs of 4 aminoglycosides and 14 β-lactams were evaluated. Combinations with amikacin demonstrated inhibitory synergistic activity in 29{\%} of the assays, as compared with 22{\%} for netilmicin (P = 0.018), 17{\%} for gentamicin (P < 0.001), and 13{\%} for tobramycin (P < 0.001). Among the β-lactams, combinations with cefoperazone, ceftriaxone, or cefpiramide (SM-1652) demonstrated inhibitory synergistic activity most often (39, 38, and 35{\%} of the assays, respectively) and with ceforanide, cefsulodin, and imipenem least often (≤8{\%} each). The most active combination was amikacin and ceftriaxone, with which 67{\%} of the assays demonstrated inhibitory synergism. Isolates with high-level resistance to either antibiotic in a combination were unlikely to be inhibited synergistically by the combination. Further, combinations generally demonstrated little synergistic activity against isolates highly susceptible to β-lactams.",
author = "Thomas Hooton and Blair, {A. D.} and M. Turck and Counts, {G. W.}",
year = "1984",
month = "1",
day = "1",
language = "English",
volume = "26",
pages = "535--538",
journal = "Antimicrobial Agents and Chemotherapy",
issn = "0066-4804",
publisher = "American Society for Microbiology",
number = "4",

}

TY - JOUR

T1 - Synergism at clinically attainable concentrations of aminoglycoside and β-lactam antibiotics

AU - Hooton, Thomas

AU - Blair, A. D.

AU - Turck, M.

AU - Counts, G. W.

PY - 1984/1/1

Y1 - 1984/1/1

N2 - We evaluated the in vitro synergistic activity at clinically attainable concentrations of combinations of aminoglycoside and β-lactam antibiotics against 30 gentamicin-resistant clinical isolates of gram-negative bacilli. All 56 pairs of 4 aminoglycosides and 14 β-lactams were evaluated. Combinations with amikacin demonstrated inhibitory synergistic activity in 29% of the assays, as compared with 22% for netilmicin (P = 0.018), 17% for gentamicin (P < 0.001), and 13% for tobramycin (P < 0.001). Among the β-lactams, combinations with cefoperazone, ceftriaxone, or cefpiramide (SM-1652) demonstrated inhibitory synergistic activity most often (39, 38, and 35% of the assays, respectively) and with ceforanide, cefsulodin, and imipenem least often (≤8% each). The most active combination was amikacin and ceftriaxone, with which 67% of the assays demonstrated inhibitory synergism. Isolates with high-level resistance to either antibiotic in a combination were unlikely to be inhibited synergistically by the combination. Further, combinations generally demonstrated little synergistic activity against isolates highly susceptible to β-lactams.

AB - We evaluated the in vitro synergistic activity at clinically attainable concentrations of combinations of aminoglycoside and β-lactam antibiotics against 30 gentamicin-resistant clinical isolates of gram-negative bacilli. All 56 pairs of 4 aminoglycosides and 14 β-lactams were evaluated. Combinations with amikacin demonstrated inhibitory synergistic activity in 29% of the assays, as compared with 22% for netilmicin (P = 0.018), 17% for gentamicin (P < 0.001), and 13% for tobramycin (P < 0.001). Among the β-lactams, combinations with cefoperazone, ceftriaxone, or cefpiramide (SM-1652) demonstrated inhibitory synergistic activity most often (39, 38, and 35% of the assays, respectively) and with ceforanide, cefsulodin, and imipenem least often (≤8% each). The most active combination was amikacin and ceftriaxone, with which 67% of the assays demonstrated inhibitory synergism. Isolates with high-level resistance to either antibiotic in a combination were unlikely to be inhibited synergistically by the combination. Further, combinations generally demonstrated little synergistic activity against isolates highly susceptible to β-lactams.

UR - http://www.scopus.com/inward/record.url?scp=0021130382&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021130382&partnerID=8YFLogxK

M3 - Article

C2 - 6517544

AN - SCOPUS:0021130382

VL - 26

SP - 535

EP - 538

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

SN - 0066-4804

IS - 4

ER -